Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atazanavir/ritonavir vs rilpivirine with tenofovir/emtricitabine for occupational HIV post-exposure prophylaxis
TCTR20190311001Phase 4Recruiting
- Sponsor
- King Chulalongkorn Memorial Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of atazanavir, ritonavir, tenofovir, emtricitabine, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by King Chulalongkorn Memorial Hospital. Started Jan 2018; status: recruiting.
02
Drugs
atazanavirritonavirtenofoviremtricitabinerilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20190311001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190311001.